As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new owner in the U.S. Rigel Pharmaceuticals will pay Blueprint $15 million to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback